Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99

Lancet

Volumn 361, Issue 9357, 2003, Pages 553-560

  Antoine, Corinne ^a   Müller, Susanna ^b   Cant, Andrew ^c   Cavazzana Calvo, Marina ^a   Veys, Paul ^d   Vossen, Jaak ^e   Fasth, Anders ^f   Heilmann, Carsten ^g   Wulffraat, Nicolas ^h   Seger, Reinhard ⁱ   Blanche, Stéphane ^a   Friedrich, Wilhelm ^b   Abinun, Mario ^c   Davies, Graham ^d   Bredius, Robert ^e   Schulz, Ansgar ^b   Landais, Paul ^a   Fischer, Alain ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^g University of Copenhagen   (Denmark)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; METHOTREXATE; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMBINED IMMUNODEFICIENCY; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPE; FOLLOW UP; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; METHODOLOGY; PHENOTYPE; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REGISTER; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0037442176     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12513-5     Document Type: Article

References (19)

1. Buckley R.H., Fischer A. Bone marrow transplantation for primary immunodeficiency diseases. Ochs H.D., Smith C.E., Puck J.M. Primary immunodeficiency disease. 1999;459-475 Oxford University Press, Oxford.
2. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 61:1983;341-348.
3. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 97:2001;1598-1603.
4. Fischer A., Friedrich W., Levinsky R., et al. Bone marrow transplantation for immunodeficiency and osteopetrosis: European survey 1968-85. Lancet. 1:1986;1080-1083.
5. Fischer A., Landais P., Friedrich W., et al. European experience of bone marrow transplantation for severe combined immunodeficiency. Lancet. 2:1990;850-854.
6. Fischer A., Landais P., Friedrich W., et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for immunodeficiency. Blood. 83:1994;1149-1154.
7. Gluckberg H., Storb R., Fefer A., et al. Clinical manifestations of GVHD in human recipients of marrow from HLA matched sibling donors. Transplant. 18:1974;295-304.
8. Przepiorka D., Weisdorf D., Martin P., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 15:1995;825-828.
9. Gentleman R, Ihaka R. The R language. In: Billard L, Fisher N, eds. The Interface Foundation of North America. Proceedings of the 28th Symposium on the Interface. 1997.
10. Ihaka R., Gentleman R. R: a language for data analysis and graphics. J Comput Graphic Statist. 5:1996;299-314.
11. Bertrand Y., Landais P., Friedrich W., et al. Influence of SCID phenotype on the outcome of HLA non identical T-cell depleted bone marrow transplantation: a retrospective European survey from the European group for BMT (EBMT) and the European Society for Immunodeficiency (ESID). J Pediatr. 134:1999;740-748.
12. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 340:1999;508-516.
13. Myers L.A., Patel D.D., Puck J.M., Buckley R.H. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 99:2002;872-878.
14. Patel D.D., Gooding M.E., Parrott R.E., Curtis K.M., Haynes B.F., Buckley R.H. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 342:2000;1325-1332.
15. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 91:1998;3646-3653.
16. Peter H.H., Friedrich W., Dopfer R., et al. NK cell function in severe combined immunodeficiency (SCID): evidence of a common T and NK cell defect in some but not all SCID patients. J Immunol. 131:1983;2332-2339.
17. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet. 357:2001;1863-1869.
18. Moshous D., Callebaut I., de Chasseval R., et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 105:2001;177-186.
19. Klein C., Cavazzana-Calvo M., Le Deist F., et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood. 85:1995;580-587.